Insider trade

Officer sold ~$439K of VRTX shares in the open market

Traded Apr 1, 2026 · Filed Apr 3, 2026

~$439K
Reported value · 978 sh @ $449.17: 22K
Holds after · shares reported: +13.3%
stock since the trade · S&P 500 +16.6%, $447.26 → $506.74 on Oct 1

Why it stands out

Vertex Pharmaceuticals's and Chief Legal Officer sold $439K of Vertex Pharmaceuticals shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Apr 1, 2026
Reporting period: Not applicable
Filed with the SEC: Apr 3, 2026

Officer$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$439,288

Shares × reported transaction price

Timing vs results

48 days after results of Feb 12, 2026, 33 days before results of May 4, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $447.26 on Apr 1, 2026, 22% above its 52-week low and 12% below its high, after a 5% drop over the previous 30 trading days

52-week range $366.54 (Aug 8, 2025) to $509.50 (Apr 30, 2025), 56% of the way up, from 251 adjusted closes. 30 trading days earlier: $470.31 on Feb 18, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Alyftrek on Mar 27, 2026, 5 days before this trade.

New use approved (efficacy supplement). Active ingredient: Deutivacaftor, Tezacaftor, Vanzacaftor Calcium. From openFDA. Dates only; no link between the two is implied